305 related articles for article (PubMed ID: 16585867)
1. Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx.
Ozer E; Grecula JC; Agrawal A; Rhoades CA; Young DC; Schuller DE
Laryngoscope; 2006 Apr; 116(4):607-12. PubMed ID: 16585867
[TBL] [Abstract][Full Text] [Related]
2. Multimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx.
Schuller DE; Grecula JC; Agrawal A; Rhoades CA; Orr DA; Young DC; Malone JP; Merz M
Cancer; 2002 Jun; 94(12):3169-78. PubMed ID: 12115349
[TBL] [Abstract][Full Text] [Related]
3. Multimodal intensification regimens for advanced, resectable, previously untreated squamous cell cancer of the oral cavity, oropharynx, or hypopharynx: a 12-year experience.
Schuller DE; Ozer E; Agrawal A; Grecula JC; Rhoades CA; Young DC
Arch Otolaryngol Head Neck Surg; 2007 Apr; 133(4):320-6. PubMed ID: 17438244
[TBL] [Abstract][Full Text] [Related]
4. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer.
Malone JP; Stephens JA; Grecula JC; Rhoades CA; Ghaheri BA; Schuller DE
Head Neck; 2004 Jul; 26(7):561-72. PubMed ID: 15229898
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.
Beckmann GK; Hoppe F; Pfreundner L; Flentje MP
Head Neck; 2005 Jan; 27(1):36-43. PubMed ID: 15459918
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study.
Lindholm P; Valavaara R; Aitasalo K; Kulmala J; Laine J; Elomaa L; Sillanmäki L; Minn H; Grénman R
Radiother Oncol; 2006 Feb; 78(2):146-51. PubMed ID: 16307813
[TBL] [Abstract][Full Text] [Related]
7. Intra-arterial chemoradiation for T3-4 oral cavity cancer: treatment outcomes in comparison to oropharyngeal and hypopharyngeal carcinoma.
Doweck I; Robbins KT; Samant S; Vieira F
World J Surg Oncol; 2008 Jan; 6():2. PubMed ID: 18194553
[TBL] [Abstract][Full Text] [Related]
8. Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.
Kovács AF; Schiemann M; Turowski B
J Craniomaxillofac Surg; 2002 Apr; 30(2):112-20. PubMed ID: 12069515
[TBL] [Abstract][Full Text] [Related]
9. Intensification regimen for advanced-stage resectable hypopharyngeal carcinoma.
Ozer E; Grecula JC; Agrawal A; Rhoades CA; Schuller DE
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):385-9. PubMed ID: 16618907
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck.
Pradier O; Christiansen H; Schmidberger H; Martin A; Jäckel MC; Steiner W; Ambrosch P; Kahler E; Hess CF
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1368-77. PubMed ID: 16169679
[TBL] [Abstract][Full Text] [Related]
11. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.
Sanguineti G; Richetti A; Bignardi M; Corvo' R; Gabriele P; Sormani MP; Antognoni P
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):762-71. PubMed ID: 15708255
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer.
Martínez-Monge R; Gómez-Iturriaga A; Cambeiro M; Garrán C; Montesdeoca N; Aristu JJ; Alcalde J
Brachytherapy; 2009; 8(1):26-33. PubMed ID: 19041280
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas.
Grecula JC; Schuller DE; Smith R; Rhoades CA; Nag S; Bauer CJ; Agrawal A; Au JL; Young D; Gahbauer RA
Cancer Invest; 2001; 19(2):127-36. PubMed ID: 11296617
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant therapy for organ preservation in head and neck cancer.
Urba SG; Wolf GT; Bradford CR; Thornton AF; Eisbruch A; Terrell JE; Carpenter V; Miller T; Tang G; Strawderman M
Laryngoscope; 2000 Dec; 110(12):2074-80. PubMed ID: 11129024
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity. Outcome of 134 patients.
Eich HT; Löschcke M; Scheer M; Kocher M; Bongartz R; Wacker S; Zöller JE; Müller RP
Strahlenther Onkol; 2008 Jan; 184(1):23-9. PubMed ID: 18188519
[TBL] [Abstract][Full Text] [Related]
17. [The role of a surgical method in combined and complex treatment of patients with squamous cell oral and oropharyngeal cancer].
Vikhlianov IV; Shoĭket IaN; Lazarev AF
Khirurgiia (Mosk); 2007; (1):55-8. PubMed ID: 17426691
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma.
Spring PM; Valentino J; Arnold SM; Sloan D; Kenady D; Kudrimoti M; Haydon RC; Lee C; Given C; Mohiuddin M; Regine WF
Cancer; 2005 Oct; 104(8):1765-71. PubMed ID: 16149090
[TBL] [Abstract][Full Text] [Related]
19. Preoperative paclitaxel/carboplatin radiochemotherapy for stage III/IV resectable oral and oropharyngeal cancer: seven-year follow-up of a phase II trial.
Eckardt A; Sinikovic B; Hofele C; Bremer M; Reuter C
Oncology; 2007; 73(3-4):198-203. PubMed ID: 18424883
[TBL] [Abstract][Full Text] [Related]
20. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
Bensadoun RJ; Bénézery K; Dassonville O; Magné N; Poissonnet G; Ramaïoli A; Lemanski C; Bourdin S; Tortochaux J; Peyrade F; Marcy PY; Chamorey E; Vallicioni J; Seng H; Alzieu C; Géry B; Chauvel P; Schneider M; Santini J; Demard F; Calais G
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):983-94. PubMed ID: 16376489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
